Targeting Mitochondrial Dysfunction
For our lead product, Imeglimin, preparations are underway for a New Drug Application in Japan. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.
View Our Candidates
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting
Shareholders approved all proposed resolutions LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for…
Read this Press Release: Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General MeetingPoxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH
The study met its key objectives; PXL770 was observed to demonstrate a consistent PK profile in the likely-NASH patient population and was observed to be safe and well-tolerated Results demonstrate target…
Read this Press Release: Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASHPoxel Announces Participation in Upcoming Virtual Investor Conferences
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Announces Participation in Upcoming Virtual Investor Conferences
Upcoming Events
European Association for the Study of the Liver 2020 International Liver Congress
